Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exact Sciences (EXAS) shares plunged Wednesday after the maker of the Cologuard colon cancer screening test reported widening losses and cut its outlook.

Cologuard Maker Exact Sciences Slashes Outlook as Losses Mount

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook. The post Exact Sciences Collapses On 'Alarming' Guidance Cut.

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

On Tuesday, Exact Sciences Corp.  EXAS reported a third-quarter EPS loss of $0.21, compared to a break-even a year ago, missing the analyst consensus loss estimate of $0.20.

Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point

EXAS' third-quarter 2024 top line benefits from broad-based momentum in Cologuard adoption and Oncotype DX's international expansion.

Exact Sciences Stock Down on Q3 Earnings & Revenue Miss, '24 View Cut

Honda

Super Micro Computer

U.S. stock futures were higher this morning, with the Dow futures gaining around 400 points on Wednesday.

Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Exact Sciences Corporation (NASDAQ:EXAS ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants Erik Holznecht - Director, Investor Relations Kevin Conroy - Chairman and CEO Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Tycho Peterson - Jefferies Andrew Brackman - William Blair Doug Schenkel - Wolfe Research Dan Brennan - Cowen Matt Sykes - Goldman Sachs Vijay Kumar - Evercore ISI Dan Arias - Stifel Jack Meehan - Nephron Research Patrick Donnelly - Citi Dan Leonard - UBS Puneet Souda - Leerink Partners Subbu Nambi - Guggenheim Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Hello. At this time, I would like to welcome everyone to the Exact Sciences Third Quarter 2024 Earnings Conference Call.

Exact Sciences Corporation (EXAS) Q3 2024 Earnings Call Transcript

Exact Sciences stock fell sharply Tuesday after the company cut its full-year outlook and posted weaker-than-expected results. The post Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook appeared first on Investor's Business Daily.

Exact Sciences Stock Falls 29% On Weak Results, Downbeat Outlook

Exact Sciences (EXAS) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to break-even earnings per share a year ago.

Exact Sciences (EXAS) Reports Q3 Loss, Lags Revenue Estimates

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 million for the third quarter ended September 30, 2024, compared to $628 million for the same period of 2023. “The Exact Sciences' team is helping eradicate cancer while strengthening our platform and growing our business efficiently,” said Kevin Conroy, chairman and CEO. “During the third quarter, we deliver.

Exact Sciences Announces Third-Quarter 2024 Results

DuPont de Nemours

Kinross Gold

We have narrowed our search to there large-cap stocks set to report results on Tuesday. These are: EXAS, DD and KGC.

3 Large-Cap Stocks to Buy Ahead of Likely Earnings Beat Tuesday

Solventum Corporation

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast. Jefferies London Healthcare Conference, London Fireside chat on Tuesday, November 19, 2024 at 6:00 a.m. ET The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. About Exact S.

Exact Sciences to Participate in November Investor Conference

Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company will present modeling data evaluating the simulated benefit and burden of established CRC screening strategies, including the Cologuard Plus™ test during the American College of Gastroenterology (ACG) Annual Meeting. ACG takes place October 25-30, 2024, in Philadelphia, Pennsylvania. Exact Sciences will also present new data on improving a.

Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement

Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.

Will Screening Sales Drive Exact Sciences' Q3 Earnings?

An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.

Can This Beaten-Down Cathie Wood Stock Bounce Back?

Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.

EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2024 financial results after the close of the U.S. financial markets on November 5, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Third quarter 2024 webcast & conference call details        .

Exact Sciences Schedules Third Quarter 2024 Earnings Call

On September 30, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, significantly increased its investment in Exact Sciences Corp (EXAS, Financial), a leader in cancer diagnostics. The firm acquired an additional 8,418,428 shares at a price of $68.12 each, elevating its total holdings to 22,042,464 shares.

FMR LLC Bolsters Stake in Exact Sciences Corp

Amgen

Biogen

bluebird bio

Bristol-Myers

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Pfizer

Recursion Pharmaceuticals

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability of successful outcomes, making it a game-changer for the biotech sector.

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.

Is EXAS Stock a Smart Addition to Your Portfolio Right Now?

Exact Sciences stock rose Friday after the FDA approved the company's next-generation colon cancer detection test, Cologuard Plus.

Exact Sciences Stock Rises After FDA Signs Off On New Cologuard

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the U.S. Food and Drug Administration (FDA) approved the Cologuard Plus™ test, the company's next generation multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1 FDA approval was based on findings from the pivotal BLUE-C study, one of the largest prospective.

FDA Approves Exact Sciences' Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer (CRC) screening test. Results show sensitivities of 88.3% for CRC and 31.2% for advanced precancerous lesions at specificity of 90.1% for negative samples confirmed by colonoscopy. Results were presented today at the European Society for Medical Oncology (ESMO) Congress in an oral presentation tit.

Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

News for Exact Sciences Stock (EXAS)